A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts
Latest Information Update: 30 Sep 2024
At a glance
- Drugs ABI-2280 (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Antiva Biosciences
Most Recent Events
- 06 Aug 2024 Planned End Date changed from 22 Aug 2025 to 28 Feb 2026.
- 18 Jul 2024 New trial record